JP2018526453A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526453A5 JP2018526453A5 JP2018531308A JP2018531308A JP2018526453A5 JP 2018526453 A5 JP2018526453 A5 JP 2018526453A5 JP 2018531308 A JP2018531308 A JP 2018531308A JP 2018531308 A JP2018531308 A JP 2018531308A JP 2018526453 A5 JP2018526453 A5 JP 2018526453A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ulbp
- cell composition
- cells
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 98
- 239000000203 mixture Substances 0.000 claims description 82
- 206010028980 Neoplasm Diseases 0.000 claims description 81
- 238000011282 treatment Methods 0.000 claims description 62
- 239000000427 antigen Substances 0.000 claims description 60
- 102000036639 antigens Human genes 0.000 claims description 60
- 108091007433 antigens Proteins 0.000 claims description 60
- 201000011510 cancer Diseases 0.000 claims description 45
- 230000001225 therapeutic effect Effects 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 29
- 230000004083 survival effect Effects 0.000 claims description 27
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 24
- 230000001939 inductive effect Effects 0.000 claims description 24
- -1 kappa or light chain Proteins 0.000 claims description 18
- 102000005962 receptors Human genes 0.000 claims description 18
- 108020003175 receptors Proteins 0.000 claims description 18
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 16
- 101000991060 Homo sapiens MHC class I polypeptide-related sequence A Proteins 0.000 claims description 12
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims description 12
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 12
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims description 12
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims description 12
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 12
- 206010029260 Neuroblastoma Diseases 0.000 claims description 12
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 12
- 239000003446 ligand Substances 0.000 claims description 12
- 210000000822 natural killer cell Anatomy 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 10
- 230000001413 cellular effect Effects 0.000 claims description 9
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 claims description 8
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 8
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 8
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 8
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims description 8
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 claims description 8
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 8
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims description 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 8
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 108060004795 Methyltransferase Proteins 0.000 claims description 8
- 102000016397 Methyltransferase Human genes 0.000 claims description 8
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 8
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 8
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 8
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 8
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 8
- 229940100198 alkylating agent Drugs 0.000 claims description 8
- 239000002168 alkylating agent Substances 0.000 claims description 8
- 208000005017 glioblastoma Diseases 0.000 claims description 8
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 claims description 6
- 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 claims description 6
- 210000000987 immune system Anatomy 0.000 claims description 6
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 4
- 102100031323 Anthrax toxin receptor 1 Human genes 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 4
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 108700012439 CA9 Proteins 0.000 claims description 4
- 102100038078 CD276 antigen Human genes 0.000 claims description 4
- 101710185679 CD276 antigen Proteins 0.000 claims description 4
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 4
- 208000004139 Choroid Plexus Neoplasms Diseases 0.000 claims description 4
- 208000037156 Choroid plexus tumor Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 4
- 102000012804 EPCAM Human genes 0.000 claims description 4
- 101150084967 EPCAM gene Proteins 0.000 claims description 4
- 102100038083 Endosialin Human genes 0.000 claims description 4
- 206010014967 Ependymoma Diseases 0.000 claims description 4
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 4
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 4
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 102000010451 Folate receptor alpha Human genes 0.000 claims description 4
- 108050001931 Folate receptor alpha Proteins 0.000 claims description 4
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 4
- 208000021309 Germ cell tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 102000010956 Glypican Human genes 0.000 claims description 4
- 108050001154 Glypican Proteins 0.000 claims description 4
- 108050007237 Glypican-3 Proteins 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 4
- 101000796095 Homo sapiens Anthrax toxin receptor 1 Proteins 0.000 claims description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 4
- 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 claims description 4
- 101000884275 Homo sapiens Endosialin Proteins 0.000 claims description 4
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 4
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 4
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 4
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 claims description 4
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 4
- 101001076732 Homo sapiens RNA-binding protein 27 Proteins 0.000 claims description 4
- 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 4
- 241000192019 Human endogenous retrovirus K Species 0.000 claims description 4
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 4
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000000172 Medulloblastoma Diseases 0.000 claims description 4
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 4
- 102000003735 Mesothelin Human genes 0.000 claims description 4
- 108090000015 Mesothelin Proteins 0.000 claims description 4
- 102000011279 Multidrug resistance protein 1 Human genes 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 claims description 4
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 claims description 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 4
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 4
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 claims description 4
- 201000004404 Neurofibroma Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 108060006580 PRAME Proteins 0.000 claims description 4
- 102000036673 PRAME Human genes 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000007641 Pinealoma Diseases 0.000 claims description 4
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 102100035703 Prostatic acid phosphatase Human genes 0.000 claims description 4
- 102000055027 Protein Methyltransferases Human genes 0.000 claims description 4
- 108700040121 Protein Methyltransferases Proteins 0.000 claims description 4
- 102100025873 RNA-binding protein 27 Human genes 0.000 claims description 4
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 claims description 4
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims description 4
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 4
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 108010002687 Survivin Proteins 0.000 claims description 4
- 101150057140 TACSTD1 gene Proteins 0.000 claims description 4
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 4
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 4
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 claims description 4
- 230000000340 anti-metabolite Effects 0.000 claims description 4
- 229940100197 antimetabolite Drugs 0.000 claims description 4
- 239000002256 antimetabolite Substances 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 201000000053 blastoma Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 4
- 201000008184 embryoma Diseases 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 230000001605 fetal effect Effects 0.000 claims description 4
- 201000010175 gallbladder cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 239000003292 glue Substances 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 230000003054 hormonal effect Effects 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 206010027191 meningioma Diseases 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 201000004058 mixed glioma Diseases 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 230000001537 neural effect Effects 0.000 claims description 4
- 208000014500 neuronal tumor Diseases 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000024724 pineal body neoplasm Diseases 0.000 claims description 4
- 208000010916 pituitary tumor Diseases 0.000 claims description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 4
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 4
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000016914 ras Proteins Human genes 0.000 claims description 4
- 108010014186 ras Proteins Proteins 0.000 claims description 4
- 210000004116 schwann cell Anatomy 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 210000000813 small intestine Anatomy 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 101150047061 tag-72 gene Proteins 0.000 claims description 4
- 229960004964 temozolomide Drugs 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims description 2
- 238000011374 additional therapy Methods 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 230000011278 mitosis Effects 0.000 claims description 2
- 230000000394 mitotic effect Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022150822A JP7662588B2 (ja) | 2015-09-03 | 2022-09-22 | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562214071P | 2015-09-03 | 2015-09-03 | |
| US62/214,071 | 2015-09-03 | ||
| PCT/US2016/050428 WO2017041106A1 (en) | 2015-09-03 | 2016-09-06 | Genetically-engineered drug resistant t cells and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022150822A Division JP7662588B2 (ja) | 2015-09-03 | 2022-09-22 | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526453A JP2018526453A (ja) | 2018-09-13 |
| JP2018526453A5 true JP2018526453A5 (enExample) | 2019-10-17 |
| JP7186615B2 JP7186615B2 (ja) | 2022-12-09 |
Family
ID=58188630
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531308A Active JP7186615B2 (ja) | 2015-09-03 | 2016-09-06 | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 |
| JP2022150822A Active JP7662588B2 (ja) | 2015-09-03 | 2022-09-22 | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022150822A Active JP7662588B2 (ja) | 2015-09-03 | 2022-09-22 | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12005078B2 (enExample) |
| EP (3) | EP4295914A3 (enExample) |
| JP (2) | JP7186615B2 (enExample) |
| KR (1) | KR20180086183A (enExample) |
| CN (1) | CN108291209A (enExample) |
| AU (2) | AU2016318163B2 (enExample) |
| CA (1) | CA2997547A1 (enExample) |
| ES (2) | ES2910709T3 (enExample) |
| IL (2) | IL257763B (enExample) |
| WO (1) | WO2017041106A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3970736A1 (en) | 2009-11-02 | 2022-03-23 | Emory University | Drug resistant immunotherapy for treatment of a cancer |
| WO2018107134A1 (en) * | 2016-12-09 | 2018-06-14 | The Uab Research Foundation | Chimeric chlorotoxin receptors |
| GB201715918D0 (en) * | 2017-09-29 | 2017-11-15 | Tc Biopharm Ltd | Modified CAR-T |
| US20210163989A1 (en) * | 2018-07-05 | 2021-06-03 | Emory University | Transduction of innate immunocompetent cells using aav6 |
| BR112021000437A2 (pt) * | 2018-07-13 | 2021-04-06 | Kyoto University | Métodos para produzir uma célula t gama delta e para prevenir ou tratar tumor, célula t gama delta, população de célula, medicamento, agente de extermínio para uma célula, e, uso da célula |
| US20210346430A9 (en) * | 2018-08-26 | 2021-11-11 | Oaiscell Biotechnologies | Method for treating glioblastoma |
| EP3877514A4 (en) * | 2018-11-08 | 2022-11-23 | IN8bio, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE199398T1 (de) | 1989-10-24 | 2001-03-15 | Chiron Corp | Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein |
| WO1997032025A1 (en) | 1996-03-01 | 1997-09-04 | Regents Of The University Of Minnesota | Method for selective engraftment of drug-resistant hematopoietic stem cells |
| US7078034B2 (en) | 1999-01-28 | 2006-07-18 | Palmetto Health Alliance | In vitro activated γ δ lymphocytes |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| JP4667451B2 (ja) | 2004-04-05 | 2011-04-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｎｋｇ２ｄの調節 |
| EP3970736A1 (en) * | 2009-11-02 | 2022-03-23 | Emory University | Drug resistant immunotherapy for treatment of a cancer |
| EP2694126A4 (en) | 2011-04-08 | 2014-12-10 | Rarecyte Inc | SYSTEMS AND METHOD FOR OBTAINING TARGET PARTICLES FROM A SUSPENSION |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| EP2968601A1 (en) | 2013-03-10 | 2016-01-20 | Baylor College Of Medicine | Chemotherapy-resistant immune cells |
| WO2015075195A1 (en) | 2013-11-22 | 2015-05-28 | Cellectis | Method of engineering chemotherapy drug resistant t-cells for immunotherapy |
| ES2792849T3 (es) * | 2014-02-10 | 2020-11-12 | Univ Emory | Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| US11135245B2 (en) | 2014-11-17 | 2021-10-05 | Adicet Bio, Inc. | Engineered γδ T-cells |
| WO2018107134A1 (en) | 2016-12-09 | 2018-06-14 | The Uab Research Foundation | Chimeric chlorotoxin receptors |
| CN114450013A (zh) | 2019-04-12 | 2022-05-06 | 爱莫里大学 | 用于促进造血细胞的细胞毒性的组合物和方法 |
| JP2024503507A (ja) | 2021-01-20 | 2024-01-25 | インエイトバイオ，インコーポレイテッド | 多価クロロトキシンキメラ抗原受容体 |
-
2016
- 2016-09-06 EP EP23194635.1A patent/EP4295914A3/en not_active Withdrawn
- 2016-09-06 KR KR1020187009488A patent/KR20180086183A/ko not_active Ceased
- 2016-09-06 AU AU2016318163A patent/AU2016318163B2/en active Active
- 2016-09-06 ES ES16843195T patent/ES2910709T3/es active Active
- 2016-09-06 US US15/756,937 patent/US12005078B2/en active Active
- 2016-09-06 JP JP2018531308A patent/JP7186615B2/ja active Active
- 2016-09-06 CA CA2997547A patent/CA2997547A1/en active Pending
- 2016-09-06 EP EP16843195.5A patent/EP3344760B1/en active Active
- 2016-09-06 ES ES22150671T patent/ES2965437T3/es active Active
- 2016-09-06 WO PCT/US2016/050428 patent/WO2017041106A1/en not_active Ceased
- 2016-09-06 CN CN201680060533.6A patent/CN108291209A/zh active Pending
- 2016-09-06 EP EP22150671.0A patent/EP4006146B1/en active Active
-
2018
- 2018-02-27 IL IL257763A patent/IL257763B/en active IP Right Grant
-
2021
- 2021-04-11 IL IL282220A patent/IL282220B/en unknown
-
2022
- 2022-09-19 AU AU2022235516A patent/AU2022235516A1/en not_active Abandoned
- 2022-09-22 JP JP2022150822A patent/JP7662588B2/ja active Active
-
2024
- 2024-05-03 US US18/654,622 patent/US20250073228A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526453A5 (enExample) | ||
| Wang et al. | The state of the art of bispecific antibodies for treating human malignancies | |
| JP2016513458A5 (enExample) | ||
| Piper et al. | Glioma stem cells as immunotherapeutic targets: advancements and challenges | |
| FI3313441T3 (fi) | Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla | |
| Wurz et al. | Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential | |
| JP2019532997A5 (enExample) | ||
| FI3455259T3 (fi) | Anti-PD-1-vasta-aineiden ja sädehoidon yhdistelmä syövän hoitoon | |
| JP2019519499A5 (enExample) | ||
| RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
| JP7662588B2 (ja) | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 | |
| JP2020510624A5 (enExample) | ||
| JP2016528195A5 (enExample) | ||
| Burnette et al. | The immunology of ablative radiation | |
| JP2016520302A5 (enExample) | ||
| JPWO2019157332A5 (enExample) | ||
| Fares et al. | Immune checkpoint inhibitors: Advances and impact in neuro-oncology | |
| Morganti et al. | Combinations using checkpoint blockade to overcome resistance | |
| Bloch | Immunotherapy for malignant gliomas | |
| JPWO2020047389A5 (enExample) | ||
| TW201734033A (zh) | 惡性病變的組合治療 | |
| Misaki et al. | Enhancement of antitumor immune response by radiation therapy combined with dual immune checkpoint inhibitor in a metastatic model of HER2-positive murine tumor | |
| Beane et al. | Novel techniques and the future of HIPEC (immunotherapy, viral therapy) | |
| Juretić | Cancer immunotherapy: Mechanism of action | |
| Belver et al. | Eric Aniogo¹, Maciej Kujawski¹, Dennis Awuah², Seung E. Cha¹, Ruby Espinosa², Susanta Hui³, Hemendra Ghimire³, Paul J. Yazaki¹, Christine E. Brown, Xiuli Wang² |